Last $0.29 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:30 PM 12/12/13 All times are local (Market data is delayed by at least 15 minutes).

reva medical inc - cdi (RVALL) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/7/14 - $0.42
52 Week Low
09/15/14 - $0.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REVA MEDICAL INC - CDI (RVALL)

Related News

No related news articles were found.

reva medical inc - cdi (RVALL) Related Businessweek News

No Related Businessweek News Found

reva medical inc - cdi (RVALL) Details

REVA Medical, Inc., a development stage medical device company, focuses on the development and commercialization of proprietary bioresorbable stent products. The company is developing and testing a bioresorbable stent to treat vascular disease in humans. Its products include ReZolve scaffold, a drug-eluting fully bioresorbable polymer stent to degrade and clear from the body. The company is also developing ReZolve2 scaffold, a drug-eluting fully bioresorbable polymer stent that is implanted using a balloon catheter to provide X-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.

46 Employees
Last Reported Date: 11/6/14
Founded in 1998

reva medical inc - cdi (RVALL) Top Compensated Officers

Co-founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $359.7K
President and Chief Operating Officer
Total Annual Compensation: $340.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $275.2K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $260.9K
Senior Vice President of Product Development
Total Annual Compensation: $254.0K
Compensation as of Fiscal Year 2013.

reva medical inc - cdi (RVALL) Key Developments

REVA Medical, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 11:30 AM

REVA Medical, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 11:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Robert B. Stockman, Co-founder, Chairman and Chief Executive Officer.

REVA Medical, Inc. Announces Auditors Changes

REVA Medical, Inc. advised that it has appointed Grant Thornton LLP as the company's independent registered public accounting firm for its fiscal year ending December 31, 2014. Grant Thornton replaces Ernst & Young LLP in this capacity and the appointment is effective December 19, 2014.

REVA Medical, Inc. Announces Change in Registered Office Address

­REVA Medical, Inc. has changed its Australian registered office address to c/o Buchan Pty. Ltd., Suite 4, Level 14, 6 O'Connell Street, Sydney, NSW 2000. The company's US registered office address remains unchanged. The company has also changed its local agent from Inteq Limited to Buchan with effect from December 5, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVALL:US $0.29 USD 0.00

RVALL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVALL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RVALL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVA MEDICAL INC - CDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at